Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Agilent Technologies launches new Dako lung cancer test in Europe

Agilent Technologies launches new Dako lung cancer test in Europe

7th April 2016

Agilent Technologies has announced the launch of a new lung cancer test, PD-L1 IHC 28-8 pharmDx, in Europe.

The test is able to identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells in order to provide information on the survival benefits associated with the lung cancer therapy Opdivo, manufactured by Bristol-Myers Squibb.

Developed by Agilent's Dako business in collaboration with Bristol-Myers Squibb, the test was recently used to assess PD-L1 expression in the phase III CheckMate 057 trial, in which Opdivo demonstrated survival benefits in patients compared to chemotherapy.

PD-L1 IHC 28-8 pharmDx becomes the first and only diagnostic assay approved to assess the survival benefit associated with Opdivo.

Jacob Thaysen, president of Agilent's diagnostics and genomics group, said: "We are excited about Agilent's involvement in the potential PD-L1 IHC 28-8 pharmDx has in helping to provide information to oncologists considering Opdivo for patients with non-squamous non-small cell lung cancer."

Lung cancer is the leading cause of cancer-related deaths worldwide. It is hoped that this test will provide additional information for physicians and inform patient dialogue.ADNFCR-8000103-ID-801816154-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.